BURROWS SCOTT L (Chief Financial Officer) sold 24.4% of their position (25.73K shares) of SPYRE THERAPEUTICS, INC. on the open market
Open‑market sale worth $2.28M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
+7.50K
Price / share
$14.50
Trade value
$108.75K
% of position
Common Stock
Shares
−900.00
Price / share
$86.25
Trade value
$77.63K
% of position
Common Stock
Shares
−4.38K
Price / share
$87.11
Trade value
$381.89K
% of position
Common Stock
Shares
−2.02K
Price / share
$88.03
Trade value
$177.47K
% of position
Common Stock
Shares
−200.00
Price / share
$89.04
Trade value
$17.81K
% of position
Common Stock
Shares
−18.23K
Price / share
$89.35
Trade value
$1.63M
% of position
Net shares
−18.23K
Net value
-$2.18M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/1/2026 | M · Option Exercise | +7.50K | $14.50 | $108.75K | 7.7% | 97.99K | 105.49K |
| Common Stock Direct | 9/1/2026 | S · Sale | −900.00 | $86.25 | $77.63K | 0.9% | 105.49K | 104.59K |
| Common Stock Direct | 9/1/2026 | S · Sale | −4.38K | $87.11 | $381.89K | 4.2% | 104.59K | 100.21K |
| Common Stock Direct | 9/1/2026 | S · Sale | −2.02K | $88.03 | $177.47K | 2.0% | 100.21K | 98.19K |
| Common Stock Direct | 9/1/2026 | S · Sale | −200.00 | $89.04 | $17.81K | 0.2% | 98.19K | 97.99K |
| Common Stock Direct | 9/2/2026 | S · Sale | −18.23K | $89.35 | $1.63M | 18.6% | 97.99K | 79.76K |
| Total | −18.23K | -$2.18M | ||||||
Stock Option (Right to Buy)
Common Stock
7.50K shares
Shares
−7.50K
Strike price
14.50
Held after
337.36K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock7.50K shares | 9/1/2026 | M · Option Exercise | −7.50K | 14.50 | — | 337.36K |